• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Azelastine - Key patent, SPC, and data exclusivity expiry (44 country coverage) Product Image

Azelastine - Key patent, SPC, and data exclusivity expiry (44 country coverage)

  • Published: September 2014
  • Genericsweb Pty Ltd – Ark Patent Intelligence

Pipeline Selector helps you avoid hours of painstaking research by quickly providing you with an accurate snapshot of a single INN, including key patents, extensions and data exclusivity expiry for 44 countries (7 country coverage also available), regulatory issues and key players.

This Pipeline Selector report covers Azelastine
Azelastine indications: Treatment of allergic rhinitis and treatment of itching of the eye associated with allergic conjunctivitis.
Azelastine innovator: Medpointe (Optivar, Astelin); Viatris (Optilast, Rhinolast); Sigma (Eyezep, Azep)

Examples of information found in this online report include:
- Includes key patent publications for 44 countries (see list below)
- Contains SPC protection for every EU state plus patent term extensions in other countries
- Data exclusivity calculated on a country by country basis
- Summary of dosage forms, strengths, indications and active ingredient forms of the brand product
- DMF & Paragraph IV filings
- Litigation alerts
- Marketing authorisation holders in selected territories
- Patent risk analysis via graphical display of data from patent filings
- Hyper-linking to crucial READ MORE >

Medpointe (Optivar, Astelin); Viatris (Optilast, Rhinolast); Sigma (Eyezep, Azep)

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos